Quantcast
Last updated on April 17, 2014 at 14:35 EDT

Latest Physiocrines Stories

2014-02-24 08:28:17

First Administration to Human Subjects of a New Protein Class, Physiocrines SAN DIEGO, Feb. 24, 2014 /PRNewswire/ -- aTyr Pharma, a rare disease therapeutics enterprise, announced today the first administration of Resokine IV to healthy human volunteers. The study is being conducted in healthy male and female volunteers in the European Union. aTyr plans to develop Resokine IV as a potential therapeutic for rare disorders where a patient's immune system is imbalanced. Resokine belongs...

2013-08-14 08:29:56

SAN DIEGO, Aug. 14, 2013 /PRNewswire/ -- aTyr Pharma, an innovative disease therapeutics enterprise, announced today the expansion of the company's executive leadership team. Ms. Kelly Blackburn joins aTyr as vice president, Clinical Affairs. Physiocrines are naturally occurring human proteins that possess novel in vivo biological activity as extracellular signaling molecules in known pathways relevant to developing protein therapeutics for a range of diseases. aTyr is advancing a...

2013-08-14 08:29:54

SAN DIEGO, Aug. 14, 2013 /PRNewswire/ -- aTyr Pharma, an innovative medical therapeutics enterprise, announced today that the United States Patent and Trademark Office (USPTO) has granted two patents that protect therapeutic and pharmaceutical compositions for two novel Physiocrines. Physiocrines are naturally occurring human proteins that possess novel in vivo biological activity as extracellular signaling molecules in known pathways relevant to developing protein therapeutics for a...

2013-07-29 08:25:51

SAN DIEGO, July 29, 2013 /PRNewswire/ -- aTyr Pharma, an innovative protein therapeutics enterprise focused on rare diseases, announced today the successful completion of a $49 million financing. A premier, global public investment fund joined existing investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Partners in the equity financing. The financing supports the clinical development of aTyr's first therapeutic program to treat rare autoimmune diseases and a rare...

2010-10-26 05:00:00

SAN DIEGO, Oct. 26 /PRNewswire/ -- aTyr Pharma, the physiocrine therapeutics company, today announced a $23 million Series C equity financing led by Domain Associates. Domain joins existing venture investors Alta Partners, Cardinal Partners and Polaris Ventures, who also participated in the financing. Proceeds will be used to accelerate the development of aTyr's preclinical pipeline and advance physiocrine drug candidates into clinical trials. Physiocrines are a recently elucidated...